Experts split over Huidagene's gene-editing trial after boy's fatal outcome
Following a child's death in Huidagene's gene-editing study, specialists reviewed the company's earlier data presentation and voiced sharply differing opinions on its scientific merit.
Three months before the fatal incident, Huidagene's former chief executive Alvin Luk shared preliminary results at a major gene-therapy symposium. One outlet provided video of that talk to several authorities in gene editing and muscular disease. After reviewing the material, the experts could not agree on the robustness of the data or the prudence of the trial design. One researcher described the work as unimpressive, while others offered more cautious appraisals. The divided feedback highlights ongoing debate over the approach used in the study that ended in tragedy.
Why it matters
The controversy spotlights safety and scientific standards in emerging gene-editing treatments after a child's death.
In this story
